Hoffmann-la Roche Inc.

Indiana University

F. Hoffmann-la Roche Ag

Roche Glycart Ag

Eike Hoffmann

Ulrich Brinkmann

Guy Georges

Stefan Dengl

Alexander Haas

Rebecca Croasdale

Michael Grote

Ekkehard Moessner

Olaf Mundigl

Werner Scheuer

Jan Olaf Stracke

Silke Metz

Christian Klein

Juergen Michael Schanzer

Joerg Benz

Klaus Mayer

Claudio Sustmann

Sebastian Dziadek

Richard Dennis DiMarchi

Pablo Umana

Konrad H Bleicher

Klaus Kaluza

Eric Argirios Kitas

Matthias Koerner

Ulrike Reiff

Birgit Bramlage

Georg Tiefenthaler

Stefan Weigand

Matthias John

Kerstin Jahn-Hofmann

Ludger Ickenstein

Wilma Lau

Anish A Konkar

Rebecca Croasdale-Wood

Wilma Dormeyer

Felix Bormann

Sara Belli

Achim Gaertner

Simone Dill

Ludger Markus Ickenstein

Herein is reported a method for the generation of multispecific antibodies by a half-antibody exchange reaction between two 2/3-IgGs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assemble full length bispecific antibodies. The method can be performed in the absence of reducing agents and does not require hinge region disulfide bonds in the starting 2/3-IgGs.

Method for generating multispecific antibodies from monospecific antibodies

Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.

Covalently linked antigen-antibody conjugates

The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Trivalent, bispecific antibodies

Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.

Covalently linked polypeptide toxin-antibody conjugates

Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.

Covalently linked helicar-anti-helicar antibody conjugates and uses thereof

Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.

Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides

The invention provides anti-theophylline antibodies and methods of using the same.

Anti-theophylline antibodies and methods of use

The invention provides anti-biotin antibodies and methods of using the same.

Anti-biotin antibodies and methods of use

The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent

This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Bi-specific digoxigenin binding antibodies

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer. 

Benzimidazole amido derivatives as kinase inhibitors

Growing community of inventors

Herrsching A. Ammersee, Germany

Eike Hoffmann